Australia's most trusted
source of pharma news
Saturday, 14 December 2024
Posted 28 February 2024 PM
Not-for-profit Crohn's Colitis Cure has opened access to its extensive real-world patient data to assist pharmaceutical companies in regulatory approvals and funding decisions.
"The key to unlocking the potential for personalised, targeted and effective therapies is access to real-world IBD patient data and insights, which will help inform regulatory approvals and speed to access," CCCure CEO, Bill Petch, said.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.